Probiotic Agents in the Treatment of Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is characterized by abdominal pain and alterations in bowel habits. Several pathogenetic factors, such as altered intestinal motility, visceral hypersensitivity, serotonin system abnormalities and psychic disturbances have been identified. Recently, a pathogenetic role of intestinal microflora has been shown in IBS: viral or bacterial infection can trigger post-infectious IBS; some patients have small intestinal bacterial overgrowth; the composition of patients' enteric flora is altered; and minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated. Probiotics may, therefore, offer a rational therapeutic approach to IBS. The data available on the use of probiotics in IBS are still limited and results of controlled clinical trials are contradictory because they have been performed using different species, dosages, treatment durations and end-points for results evaluation. A critical evaluation of the therapeutic role of the various probiotics in IBS is presented in this article.

[1]  T. Piche.  Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. , 2007 .

[2]  H. Szajewska,et al.  A randomized double‐blind placebo‐controlled trial of Lactobacillus GG for abdominal pain disorders in children , 2006, Alimentary pharmacology & therapeutics.

[3]  B. Cash,et al.  Probiotic use in irritable bowel syndrome , 2006, Current gastroenterology reports.

[4]  M. Riddle,et al.  Postinfectious Irritable Bowel Syndrome—A Meta-Analysis , 2006, The American Journal of Gastroenterology.

[5]  P. Whorwell,et al.  Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.

[6]  R. Spiller,et al.  Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes , 2006, The American Journal of Gastroenterology.

[7]  L. Mcfarland.  Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease , 2006, The American Journal of Gastroenterology.

[8]  R JoséKlinger,et al.  Irritable Bowel Syndrome , 2006 .

[9]  J. Buts,et al.  Effects of Saccharomyces boulardii on Intestinal Mucosa , 2006, Digestive Diseases and Sciences.

[10]  N. Vaisman,et al.  The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. , 2005, Clinical nutrition.

[11]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  R. Baldassano,et al.  A Randomized, Double‐blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohn's Disease , 2005, Inflammatory bowel diseases.

[13]  M. Färkkilä,et al.  A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention , 2005, Alimentary pharmacology & therapeutics.

[14]  M. Bauserman,et al.  The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. , 2005, The Journal of pediatrics.

[15]  B. Walters,et al.  Detection of Bacterial Overgrowth in IBS Using the Lactulose H2 Breath Test: Comparison with 14C-d-Xylose and Healthy Controls , 2005, The American Journal of Gastroenterology.

[16]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[17]  A. Palva,et al.  Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR , 2005, The American Journal of Gastroenterology.

[18]  F. Marotta,et al.  Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. , 2004, Chinese journal of digestive diseases.

[19]  W. Chey,et al.  Irritable bowel syndrome: a systematic review , 2004 .

[20]  Henry C. Lin,et al.  Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. , 2004, JAMA.

[21]  A. Saggioro.  Probiotics in The Treatment of Irritable Bowel Syndrome , 2004, Journal of clinical gastroenterology.

[22]  A. Roalfe,et al.  Prevalence of irritable bowel syndrome: a community survey. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[23]  Yu-jing Fan,et al.  Intestinal microecology and quality of life in irritable bowel syndrome patients. , 2004, World journal of gastroenterology.

[24]  R. Spiller.  Infection, immune function, and functional gut disorders. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  H. Herfarth,et al.  Lactobacillus GG in inducing and maintaining remission of Crohn's disease , 2004, BMC gastroenterology.

[26]  J. Hunter,et al.  Effect of Lactobacillus plantarum 299v on Colonic Fermentation and Symptoms of Irritable Bowel Syndrome , 2002, Digestive Diseases and Sciences.

[27]  P. Testoni,et al.  Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease , 2000, Digestive Diseases and Sciences.

[28]  Jian-MinSi,et al.  Intestinal microecology and quality of life in irritable bowel syndrome patients , 2004 .

[29]  N. Read,et al.  Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome , 2003, Gut.

[30]  Henry C. Lin,et al.  Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study , 2003, American Journal of Gastroenterology.

[31]  H. Mertz.  Irritable bowel syndrome. , 2000, The New England journal of medicine.

[32]  C. Prantera,et al.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG , 2002, Gut.

[33]  B. Birkenfeld,et al.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome , 2001, European journal of gastroenterology & hepatology.

[34]  G. Barbara,et al.  Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. , 2001, Gastroenterology.

[35]  J. Malagelada,et al.  Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome , 2001, Gut.

[36]  T. Imperiale,et al.  Pharmacologic Treatment of the Irritable Bowel Syndrome , 2000, Annals of Internal Medicine.

[37]  M. Ohto,et al.  Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[38]  C. O'Morain,et al.  Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[39]  Corazza,et al.  Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth , 2000, Alimentary pharmacology & therapeutics.

[40]  S. Ahrné,et al.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[41]  B. Flourié,et al.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. , 1999, Gastroenterology.

[42]  A. Ruigómez,et al.  Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study , 1999, BMJ.

[43]  M. Elia,et al.  Abnormal colonic fermentation in irritable bowel syndrome , 1998, The Lancet.

[44]  M. Delforge,et al.  TREATMENT OF IRRITABLE BOWEL SYNDROME DOUBLE BLIND TRIAL OF SACCHAROMYCES BOULARDII , 1983 .

[45]  A. Balsari,et al.  The fecal microbial population in the irritable bowel syndrome. , 1982, Microbiologica.